References
- Akizawa H, Uehara T, Arano Y. (2008). Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev 60:1319–28.
- Antczak C, De Meester I, Bauvois B. (2001). Ectopeptidases in pathophysiology. BioEssays 23:251–60.
- Bayes-Genis A, Barallat J, Richards AM. (2016). A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol 68:639–53.
- Drug Metabolism Discussion Group (DMDG). Available from: www.dmdg.org [last accessed 9 June 2020].
- Esposito S, de Leonibus ML, Ingenito R, et al. (2018). A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides. J Pharm Biomed 159:449–58.
- European Medicines Agency (EMA). (2011). Guideline on bioanalytical method validation. Available from: www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf [accessed 09 June 2020].
- European Medicines Agency (EMA). (2013). Guideline on the investigation of drug interactions, Available from: www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions_en.pdf [last accessed 09 June 2020].
- Henderson CJ, Kapelyukh Y, Scheer N, et al. (2019). An extensively humanized mouse model to predict pathways of drug disposition and drug/drug interactions, and to facilitate design of clinical trials. Drug Metab Dispos 47:601–15.
- Sonesson A, Brady K, Bjørnsdottir I, Christensen JK. (2020). Meeting report: 1st Workshop of the Peptide ADME Discussion Group. Xenobiotica.
- US Food and Drug Administration (FDA). (2016). Guidance, safety testing of drug metabolites. Available from: www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-drug-metabolites (NB 2020 guidance supersedes the guidance of the same name published in 2016) [last accessed 9 June 2020].
- US Food and Drug Administration (FDA). (2018). Guidance, bioanalytical method validation. Available from: www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry [last accessed 9 June 2020].
- Vegt E, de Jong M, Wetzels JFM, et al. (2010). Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 51:1049–58.]